Keywords: مهارکننده های mTOR; 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; AA; amino acid; AFP; alpha fetoprotein; AML; actue myeloid leukemia; Ang2; angiopoietin 2; ATP; adenosine triphosphate; BCLC; Barcelona-Clinic Liver Cancer classification; BSC; best supportive care; CAP
مقالات ISI مهارکننده های mTOR (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهارکننده های mTOR; Antiangiogenic therapy; Metastatic renal-cell carcinoma; mTOR inhibitors; Prognostic factors; Survival; Targeted therapy;
Keywords: مهارکننده های mTOR; tuberous sclerosis complex; mTOR inhibitors; SEGA; everolimus; hydrocephalus; treatment;
Keywords: مهارکننده های mTOR; Bladder cancer; Renal transplant; Recurrence; mTOR inhibitors; Tumor vesical; Trasplante renal; Recurrencia; Inhibidores de mTOR;
Keywords: مهارکننده های mTOR; Renal cell carcinoma; Tyrosine kinase inhibitors; Anti-VEGF inhibitors; mTOR inhibitors; Immune checkpoint inhibitors; IDO1 inhibitor; Glutaminase inhibitor; CXCR4 antagonist; Transglutaminase 2 inhibitor;
Keywords: مهارکننده های mTOR; Carcinoma renal; Cirugía conservadora; Inhibidores mTORRenal carcinoma; Conservative surgery; mTOR inhibitors
Keywords: مهارکننده های mTOR; anti-VEGF; CNS metastasis; Kidney cancer; mTOR inhibitors; Survival;
Keywords: مهارکننده های mTOR; subependymal giant cell astrocytoma; tuberous sclerosis complex; outcome; surgery; prognostic factor; mTOR inhibitors;
Keywords: مهارکننده های mTOR; Hemodialysis; Kidney cancer; Kidney disease; mTOR inhibitors; VEGF tyrosine kinase inhibitors
Keywords: مهارکننده های mTOR; Inmunosupresión; Inhibidores mTOR; Trasplante renal; Cáncer cutáneo; Immunosuppression; mTOR inhibitors; Renal transplant; Skin cancer;
Keywords: مهارکننده های mTOR; Bisphosphonates; Bone metastases; mTOR inhibitors; Renal cell carcinoma; VEGF-targeted therapy;
Keywords: مهارکننده های mTOR; Bone metastases; Liver metastases; mTOR inhibitors; Outcome; Renal cell carcinoma; VEGF therapy;
Keywords: مهارکننده های mTOR; Dendritic cells; Calcineurin inhibitors; mTOR inhibitors; Transplantation; Immunosuppression; Flow cytometry
Keywords: مهارکننده های mTOR; Renal transplantation; Chronic allograft nephropathy; mTOR inhibitors
Dramatic relapse of seizures after everolimus withdrawal
Keywords: مهارکننده های mTOR; Everolimus; Subependymal giant cell astrocytoma; SEGA; Tuberous sclerosis complex; Epilepsy; mTOR inhibitors;
Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland
Keywords: مهارکننده های mTOR; mTOR inhibitors; Sequential therapy in mRCC, Swiss mRCC cohort; Tyrosine kinase inhibitor (TKI); VEGF-targeted therapy;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
Keywords: مهارکننده های mTOR; BCR-ABL kinase inhibitors; Ibrutinib; Idelalisib; Infection; Janus kinase inhibitors; mTOR inhibitors; Small-molecule inhibitors;
Liver Angiomyolipomas in Tuberous Sclerosis Complex-Their Incidence and Course
Keywords: مهارکننده های mTOR; tuberous sclerosis; mTOR; angiomyolipoma; mTOR inhibitors; everolimus; TSC1; TSC2;
The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review
Keywords: مهارکننده های mTOR; Circulating endothelial cells; Endothelial colony forming cells; Renal cell carcinoma; Resistance; Antiangiogenic agents; mTOR inhibitors;
Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors
Keywords: مهارکننده های mTOR; AP-1; activator protein 1; CNI; calcineurin inhibitor(s); ECM; extracellular matrix; EMT; epithelial to mesenchymal transition; ERK; extracellular signal regulated kinase; FKBP; FK506 binding protein; JNK; Jun N-terminal kinase; LAP; latency-associated pr
Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma
Keywords: مهارکننده های mTOR; Mevalonate pathway; Statins; mTOR inhibitors; Retinoblastoma protein; Renal cell carcinoma;
Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors
Keywords: مهارکننده های mTOR; Mammalian target of rapamycin; mTOR inhibitors; 3H-Imidazo [4,5-b] pyridine; Antitumor; Synthesis;
Huge soft tissue PEComa with aggressive lung and bone metastases
Keywords: مهارکننده های mTOR; Perivascular epithelioid cell tumors; Mammalian target of rapamycin; mTOR inhibitors;
Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy
Keywords: مهارکننده های mTOR; Tuberous sclerosis; Autosomal dominant polycystic kidney disease; ADPKD; Angiomyolipoma; mTOR inhibitors; Contiguous gene syndrome; TSC2/PKD1; Esclerosis tuberosa; Poliquistosis renal autosómica dominante; PQRAD; Angiomiolipoma; Inhibidores de mTOR; SÃn
Opciones terapéuticas y factores predictivos de recurrencia y mortalidad cáncer-especÃï¬ca en pacientes con tumor vesical después de trasplante renal: análisis multiinstitucional
Keywords: مهارکننده های mTOR; Tumor vesical; Trasplante renal; Recurrencia; Inhibidores de mTOR; Bladder cancer; Renal transplant; Recurrence; mTOR inhibitors;
Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors
Keywords: مهارکننده های mTOR; Imidazo[1,2-b]pyridazine; mTOR inhibitors; Anti-proliferative activity; Anticancer;
Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2
Keywords: مهارکننده های mTOR; Belatacept; Costimulation blockade; mTOR inhibitors; Renal injury;
Management of side effects of mTOR inhibitors in tuberous sclerosis patients
Keywords: مهارکننده های mTOR; mTOR inhibitors; Sirolimus; Everolimus; Tuberous sclerosis complex
Index of microvascular resistance after early conversion from calcineurin inhibitor to everolimus in heart transplantation: A sub-study to a 1-year randomized trial
Keywords: مهارکننده های mTOR; coronary physiology; coronary microcirculation; index of microvascular resistance (IMR); heart transplantation; everolimus; mTOR inhibitors;
Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature
Keywords: مهارکننده های mTOR; tuberous sclerosis; rapamycin; mTOR inhibitors; angiofibroma;
Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition
Keywords: مهارکننده های mTOR; Akt; protein kinase B; BSA; bovine serum albumin; CRP; C-reactive protein; CsA; cyclosporine A; CV; coefficient of variation; EDTA; ethylenediaminetetraacetic acid; ELISA; enzyme-linked, immunosorbent assay; ERK; extracellular signal-regulated kinase; Evr
mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis
Keywords: مهارکننده های mTOR; mTOR; mTOR inhibitors; Epilepsy; Epileptogenesis; Tuberous sclerosis complex; Animal epilepsy models;
Use of mTOR Inhibitor Everolimus in Three Neonates for Treatment of Tumors Associated With Tuberous Sclerosis Complex
Keywords: مهارکننده های mTOR; tuberous sclerosis complex; mTOR inhibitors; cardiac rhabdomyoma; subependymal giant cell astrocytoma
Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data
Keywords: مهارکننده های mTOR; mRCC; mTOR inhibitors; Second-line; Sequence of therapy;
Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization
Keywords: مهارکننده های mTOR; Kidney cancer; Clear cell renal carcinoma; Targeted therapies; Predictive biomarkers; Antiangiogenics; mTOR inhibitors
mTOR inhibitors and diabetes
Keywords: مهارکننده های mTOR; mTOR inhibitors; Diabetes; Hyperglycemia; Cancer; Everolimus; Temsirolimus
Role of mTOR inhibitors in epilepsy treatment
Keywords: مهارکننده های mTOR; Epilepsy; Epileptogenesis; mTOR inhibitors; Tuberous sclerosis; Rapamycin;
Cáncer de mama con receptores hormonales positivos: tratamiento adyuvante, primera línea en cáncer metastásico y nuevas estrategias (inhibición de mTOR)
Keywords: مهارکننده های mTOR; Cáncer de mama; Resistencia endocrina; Everolimus; Inhibidores de mTOR; TemsirolimusBreast cancer; Endocrine resistance; Everolimus; mTOR inhibitors; Temsirolimus
Topical Everolimus for Facial Angiofibromas in the Tuberous Sclerosis Complex. A First Case Report
Keywords: مهارکننده های mTOR; topical everolimus; facial angiofibromas; mTOR inhibitors; tuberous sclerosis complex;
Early Neurodevelopmental Screening in Tuberous Sclerosis Complex: A Potential Window of Opportunity
Keywords: مهارکننده های mTOR; development; tuberous sclerosis; vigabatrin; everolimus; sirolimus; cognition; Capute Scales; mTOR inhibitors;
Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer
Keywords: مهارکننده های mTOR; Everolimus; mTOR inhibitors; Noninfectious pneumonitis; Cough; Dyspnea; Breast cancer;
The Role of New Immunosuppressive Drugs in Nonmelanoma Skin Cancer in Renal Transplant Recipients
Keywords: مهارکننده های mTOR; Immunosuppression; mTOR inhibitors; Renal transplant; Skin cancerInmunosupresión; Inhibidores mTOR; Trasplante renal; Cáncer cutáneo
Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure-response relationships, and clinical outcomes
Keywords: مهارکننده های mTOR; mTOR inhibitors; Calcineurin inhibitors; Tacrolimus; Renal transplantation; Pharmacokinetics; Therapeutic drug monitoring;
Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
Keywords: مهارکننده های mTOR; Autophagy; Clinical trials; Drug resistance; Mammalian target of rapamycin; mTOR inhibitors; Renal cell carcinoma;
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer
Keywords: مهارکننده های mTOR; Temsirolimus; mTOR inhibitors; Endometrial cancer; Predictors of response;
Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an Italian Center
Keywords: مهارکننده های mTOR; mTOR inhibitors; Pancreas; Renal cell carcinoma; Targeted therapy; Tyrosine kinase inhibitors
A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients
Keywords: مهارکننده های mTOR; mTOR inhibitors; Stomatitis; Mucositis; Cancer; Toxicities
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications
Keywords: مهارکننده های mTOR; mTOR inhibitors; Oral Intravenous; Metastatic renal cell carcinoma; mRCC; Pharmacokinetics
Differentiating mTOR inhibitors in renal cell carcinoma
Keywords: مهارکننده های mTOR; mTOR inhibitors; Renal cell carcinoma; Temsirolimus; Everolimus; Treatment; PI3K/Akt/mTOR pathway
mTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice
Keywords: مهارکننده های mTOR; Temsirolimus; Everolimus; Kidney cancer; mTOR inhibitors